UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
EARLY_PHASE1
36
about 5.9 years
0.0833333333333333–30
1 site in TX
What this study is about
This trial is testing a treatment to see if it's safe and effective in replacing some chemotherapy cycles with other treatments for children newly diagnosed with acute myeloid leukemia (AML). The goal is to improve survival while reducing long-term side effects. Researchers will monitor participants for up to three years after enrollment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Intrathecal triple
- 2.SOC
- 3.Take Asparaginase Erwinia Chrysanthemi (recombinant)
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS, cytarabine, etoposide, fludarabine, Antineoplastic Agent [TC] (Topoisomerase 2 Inhibitors), venetoclax
injection (Injection), injection, intravenous, oral (Oral Capsule), oral
Primary: Tolerability rate of Ida-FLA, Tolerability rate of VIA for HR patients, Tolerability rate of VIA for IR patients
Secondary: 3 year event-free survival, 3 year overall survival, Complete remission rate, Tolerability rate of intensified regimen as a whole for HR patients, Tolerability rate of intensified regimen as a whole for IR patients
Oncology